Base de dados : MEDLINE
Pesquisa : C11.338.250 [Categoria DeCS]
Referências encontradas : 1181 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 119 ir para página                         

  1 / 1181 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29403334
[Au] Autor:Clark J; Randolph J; Sokol JA; Moore NA; Lee HBH; Nunery WR
[Ad] Endereço:Department of Ophthalmology and Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, Kentucky.
[Ti] Título:Surgical approach to limiting skin contracture following protractor myectomy for essential blepharospasm.
[So] Source:Digit J Ophthalmol;23(4):8-12, 2017.
[Is] ISSN:1542-8958
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: To report our experience with protractor myectomy in patients with benign essential blepharospasm who did not respond to serial botulinum toxin injection, and to describe intra- and postoperative techniques that limited skin contracture while also providing excellent functional and cosmetic results. Methods: The medical records of patients with isolated, benign, essential blepharospasm who underwent protractor myectomy from 2005 to 2008 by a single surgeon were reviewed retrospectively. The technique entailed operating on a single eyelid during each procedure, using a complete en bloc resection of all orbicularis tissue, leaving all eyelid skin intact at the time of surgery, and placing the lid under stretch with Frost suture and applying a pressure dressing for 5-7 days. Results: Data from 28 eyelids in 7 patients were included. Average follow-up was 21.5 months (range, 4-76 months). Of the 28 eyelids, 20 (71.4%) showed postoperative resolution of spasm, with no further need for botulinum toxin injections. In the 8 eyelids requiring further injections, the average time to injection after surgery was 194 days (range, 78-323 days), and the average number of injections was 12 (range, 2-23 injections). All but one eyelid had excellent cosmetic results, without signs of contracture; one eyelid developed postoperative skin contracture following premature removal of the Frost suture and pressure dressing because of concerns over increased intraocular pressure. Conclusions: In our patient cohort, this modified technique resulted in excellent cosmetic and functional results and limited postoperative skin contracture.
[Mh] Termos MeSH primário: Blefarospasmo/cirurgia
Contratura/cirurgia
Pálpebras/cirurgia
Músculos Oculomotores/cirurgia
Procedimentos Cirúrgicos Oftalmológicos/métodos
Complicações Pós-Operatórias/cirurgia
Dermatopatias/cirurgia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Contratura/diagnóstico
Contratura/etiologia
Pálpebras/patologia
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Procedimentos Cirúrgicos Oftalmológicos/efeitos adversos
Complicações Pós-Operatórias/diagnóstico
Complicações Pós-Operatórias/etiologia
Reoperação
Estudos Retrospectivos
Pele/patologia
Dermatopatias/diagnóstico
Dermatopatias/etiologia
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE
[do] DOI:10.5693/djo.01.2016.11.001


  2 / 1181 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28388718
[Au] Autor:Monheit GD; Pickett A
[Ad] Endereço:Dermatologist, Departments of Dermatology and Ophthalmology, University of Alabama at Birmingham, Birmingham, AL, USA.
[Ti] Título:AbobotulinumtoxinA: A 25-Year History.
[So] Source:Aesthet Surg J;37(suppl_1):S4-S11, 2017 05 01.
[Is] ISSN:1527-330X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:During the late 1960s and early 1970s, Alan Scott showed that intramuscular injections of botulinum toxin (BoNT) corrected nonaccommodative strabismus without resorting to surgery. The UK doctors who trained with Scott soon realized the significant potential offered by BoNT type A as a therapeutic option for several difficult-to-treat diseases. This led to a collaboration between these pioneering clinicians and the Centre for Applied Microbiology and Research at Porton Down, United Kingdom, and, in turn, to the development and commercialization of abobotulinumtoxinA as Dysport (Dystonia/Porton Down; Ipsen Biopharm Ltd., Wrexham, UK). Dysport was approved in Europe for the treatment of specific dystonias in December 1990 and now has marketing authorizations in 75 countries. Since then, the use of BoNT in therapeutic and aesthetic indications has grown year-on-year, and continues to expand well beyond Scott's initial aim. For example, ongoing trials are assessing potential new indications for BoNT-A, including acne and psoriasis. Furthermore, a growing number of other BoNT products, often termed "biosimilars," together with innovative formulations of well-established BoNT types, are likely to reach the market over the next few years. This review focuses on the history of Dysport to mark the 25th anniversary of its first launch in the United Kingdom.
[Mh] Termos MeSH primário: Toxinas Botulínicas Tipo A/uso terapêutico
Técnicas Cosméticas/tendências
Fármacos Neuromusculares/uso terapêutico
Envelhecimento da Pele/efeitos dos fármacos
[Mh] Termos MeSH secundário: Acne Vulgar/tratamento farmacológico
Medicamentos Biossimilares/administração & dosagem
Medicamentos Biossimilares/uso terapêutico
Blefarospasmo/tratamento farmacológico
Toxinas Botulínicas Tipo A/administração & dosagem
Ensaios Clínicos como Assunto
Clostridium botulinum/metabolismo
Músculos Faciais/efeitos dos fármacos
Seres Humanos
Hiperidrose/tratamento farmacológico
Injeções Intramusculares/métodos
Fármacos Neuromusculares/administração & dosagem
Síndrome da Dor Patelofemoral/tratamento farmacológico
Psoríase/tratamento farmacológico
Estrabismo/tratamento farmacológico
Reino Unido
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biosimilar Pharmaceuticals); 0 (Neuromuscular Agents); E211KPY694 (onabotulinumtoxinA); EC 3.4.24.69 (Botulinum Toxins, Type A); EC 3.4.24.69 (abobotulinumtoxinA); EC 3.4.24.69 (incobotulinumtoxinA)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170408
[St] Status:MEDLINE
[do] DOI:10.1093/asj/sjw284


  3 / 1181 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28239516
[Au] Autor:Yang J; Shao N; Song W; Wei Q; Ou R; Wu Y; Shang HF
[Ad] Endereço:Department of Neurology West China Hospital Sichuan University Chengdu Sichuan China.
[Ti] Título:Nonmotor symptoms in primary adult-onset cervical dystonia and blepharospasm.
[So] Source:Brain Behav;7(2):e00592, 2017 Feb.
[Is] ISSN:2162-3279
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The nature and frequency of nonmotor symptoms in primary adult-onset cervical dystonia (CD) and blepharospasm (BSP) patients in Chinese populations remain unknown. METHODS: Hamilton's Depression Scale (HAMD), Hamilton's Anxiety Scale (HAMA), Addenbrooke's Cognitive Examination Revised (ACE-R), Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale were used to evaluate NMS in 120 patients with primary focal adult-onset dystonia (60 with BSP and 60 with CD) and 60 age-, sex-, and education level- matched healthy controls (HCs). Motor symptoms of BSP and CD patients were evaluated by Jankovic rating scale and Toronto Western Spasmodic Torticollis Rating Scale-severity scale separately. RESULTS: Twenty patients had depression, and 29 patients had anxiety. The mean HAMD and HAMA scores were significantly higher in patient groups. Thirty-six patients had cognitive decline based on the cut-off score of 75. The total score and scores of each domain of ACE-R were significantly lower in patient groups than that in HCs. Quality of sleep was impaired in patient groups, and patients with CD had worse quality of sleep than patients with BSP. Thirty-three BSP patients and 43 CD patients suffered from sleep disorder separately. The frequency of excessive daytime sleepiness did not differ between patients and HCs. No significant correlation was found between NMS and motor severity in the two forms of dystonia. CONCLUSIONS: Current study suggests that NMS are prevalent in Chinese CD and BSP patients, and the motor severity of dystonia did not contribute to the severity of nonmotor symptoms. Assessment of nonmotor symptoms should be considered in clinical management of focal dystonia.
[Mh] Termos MeSH primário: Ansiedade/epidemiologia
Blefarospasmo/epidemiologia
Depressão/epidemiologia
Distonia/congênito
Transtornos do Sono-Vigília/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Idade de Início
Idoso
Ansiedade/etiologia
Ansiedade/fisiopatologia
Blefarospasmo/complicações
Blefarospasmo/fisiopatologia
China/epidemiologia
Depressão/etiologia
Depressão/fisiopatologia
Distonia/complicações
Distonia/epidemiologia
Distonia/fisiopatologia
Feminino
Seres Humanos
Masculino
Meia-Idade
Índice de Gravidade de Doença
Transtornos do Sono-Vigília/etiologia
Transtornos do Sono-Vigília/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170228
[St] Status:MEDLINE
[do] DOI:10.1002/brb3.592


  4 / 1181 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28186662
[Au] Autor:Defazio G; Hallett M; Jinnah HA; Conte A; Berardelli A
[Ad] Endereço:Department of Basic Medical Sciences, Neurosciences and Sensory Organs, "Aldo Moro", University of Bari, Bari, Italy.
[Ti] Título:Blepharospasm 40 years later.
[So] Source:Mov Disord;32(4):498-509, 2017 04.
[Is] ISSN:1531-8257
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Forty years ago, C.D. Marsden proposed that blepharospasm should be considered a form of adult-onset focal dystonia. In the present paper, we provide a comprehensive overview of the findings regarding blepharospasm reported in the past 40 years. Although prolonged spasms of the orbicularis oculi muscles remain the clinical hallmark of blepharospasm, patients with blepharospasm may be characterized by various types of involuntary activation of periocular muscles. In addition to motor features, blepharospasm patients may also have nonmotor manifestations, including psychiatric, mild cognitive, and sensory disturbances. The various motor and nonmotor symptoms are not present in all patients, suggesting that blepharospasm is phenomenologically a heterogeneous condition. This emphasizes the need for tools for severity assessment that take into account both motor and nonmotor manifestations. The cause of blepharospasm remains elusive, but several lines of evidence indicate that blepharospasm is a multifactorial condition in which one, or several, as yet unknown genes together with epigenetic and environmental factors combine to reach the threshold of the disease. Although blepharospasm was originally believed to be solely a basal ganglia disorder, neurophysiological and neuroimaging evidence point to anatomical and functional involvement of several brain regions. The contribution of multiple areas has led to the hypothesis that blepharospasm should be considered as a network disorder, and this might reflect the varying occurrence of motor and nonmotor manifestations in blepharospasm patients. Despite advances in the aetiology and pathophysiology, treatment remains symptomatic. © 2017 International Parkinson and Movement Disorder Society.
[Mh] Termos MeSH primário: Blefarospasmo/epidemiologia
Blefarospasmo/fisiopatologia
[Mh] Termos MeSH secundário: Blefarospasmo/terapia
Transtornos Cognitivos/complicações
Seres Humanos
Estudos Longitudinais
Transtornos Mentais/complicações
Transtornos dos Movimentos/complicações
Prevalência
Transtornos do Sono-Vigília/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, N.I.H., INTRAMURAL
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170211
[St] Status:MEDLINE
[do] DOI:10.1002/mds.26934


  5 / 1181 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28145664
[Au] Autor:Wilkes J
[Ti] Título:AAN Updates Guidelines on the Uses of Botulinum Neurotoxin.
[So] Source:Am Fam Physician;95(3):198-199, 2017 Feb 01.
[Is] ISSN:1532-0650
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Blefarospasmo/tratamento farmacológico
Toxinas Botulínicas Tipo A/uso terapêutico
Cefaleia/tratamento farmacológico
Espasticidade Muscular/tratamento farmacológico
Neurotoxinas/uso terapêutico
Torcicolo/tratamento farmacológico
[Mh] Termos MeSH secundário: Toxinas Botulínicas Tipo A/administração & dosagem
Seres Humanos
Neurotoxinas/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Neurotoxins); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170202
[St] Status:MEDLINE


  6 / 1181 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28017248
[Au] Autor:Vijayakumar D; Wijemanne S; Jankovic J
[Ad] Endereço:Parkinson's Disease Center and Movement Disorder Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, United States.
[Ti] Título:Treatment of blepharospasm with apraclonidine.
[So] Source:J Neurol Sci;372:57-59, 2017 Jan 15.
[Is] ISSN:1878-5883
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To describe improvement in blepharospasm with apraclonidine. BACKGROUND: Blepharospasm is a focal dystonia involving chiefly the orbicularis oculi and periocular muscles resulting in involuntary sustained eyelid closure. Botulinum toxin injection is the mainstay of treatment with meaningful improvement in over 85% of patients, but the effects often wear off within 3-4months. Apraclonidine is an alpha-2 adrenergic receptor agonist, which causes contraction of superior tarsal (Müller) muscle which may improve blepharospasm-related eyelid closure. We propose that apraclonidine may be a useful short-term treatment in patients with blepharospasm, particularly during wearing off from botulinum toxin injection. METHODS: Patients who had pre-mature wearing off of botulinum injection effect were evaluated before and after the administration of 2 drops of apraclonidine 0.5%-1% solution to each eye. Subjective patient impressions and examiner's impression of symptoms pre and post-apraclonidine administration were recorded. A blinded rater evaluated the videos and provided an independent assessment of the severity of symptoms pre- and post-administration, using a 0-4 scale. RESULTS: Our study included 7 patients (4 male) with a mean age of 61years and mean duration of blepharospasm of 3.6years. There was a subjective, albeit transient (about 2-4h) improvement in blepharospasm reported by all patients and by the examiner. The mean severity scores, based on blinded video ratings, showed a reduction from of 3.4 pre-administration to 2.3 post-administration of apraclonidine (p<0.025). No adverse effects were noted. CONCLUSIONS: Apraclonidine is a potentially useful medication for short term management of blepharospasm symptoms while awaiting botulinum toxin injection.
[Mh] Termos MeSH primário: Agonistas de Receptores Adrenérgicos alfa 2/uso terapêutico
Blefarospasmo/tratamento farmacológico
Clonidina/análogos & derivados
[Mh] Termos MeSH secundário: Idoso
Toxinas Botulínicas/uso terapêutico
Clonidina/uso terapêutico
Feminino
Seres Humanos
Masculino
Meia-Idade
Neurotoxinas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; VIDEO-AUDIO MEDIA
[Nm] Nome de substância:
0 (Adrenergic alpha-2 Receptor Agonists); 0 (Neurotoxins); 843CEN85DI (apraclonidine); EC 3.4.24.69 (Botulinum Toxins); MN3L5RMN02 (Clonidine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161227
[St] Status:MEDLINE


  7 / 1181 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27672032
[Au] Autor:Trebossen V; Bouaziz N; Benadhira R; Januel D
[Ad] Endereço:Unité de recherche clinique, Pôle G03, EPS Ville Evrard, 202 avenue Jean Jaurès, 93330, Neuilly sur Marne, France.
[Ti] Título:Transcranial direct current stimulation for patients with benign essential blepharospasm: a case report.
[So] Source:Neurol Sci;38(1):201-202, 2017 Jan.
[Is] ISSN:1590-3478
[Cp] País de publicação:Italy
[La] Idioma:eng
[Mh] Termos MeSH primário: Blefarospasmo/terapia
Estimulação Transcraniana por Corrente Contínua
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160928
[St] Status:MEDLINE
[do] DOI:10.1007/s10072-016-2703-x


  8 / 1181 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27658142
[Au] Autor:Arora T; Maharshi V; Rehan HS; Nagar P
[Ti] Título:Blepharospasm: an uncommon adverse effect caused by long-term administration of olanzapine.
[So] Source:J Basic Clin Physiol Pharmacol;28(1):85-87, 2017 Jan 01.
[Is] ISSN:2191-0286
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Blepharospasm is one of the components of drug-induced Meige's syndrome which is reported to be caused by typical antipsychotics. Reports of blepharospasm or Meige's syndrome caused by atypical antipsychotics are rare. CASE: A 30-year-old female patient presented to psychiatry out patient department (OPD) with chief complaints of inability to keep her eyes open for long and excessive blinking for 2 months, irritation of eyes, watery discharge from eyes and photophobia for last 1 month. The patient had been taking olanzapine 10 mg, sertraline 100 mg and divalproex sodium 500 mg per orally on once a day basis for the management of major depressive disorder with psychotic features for last 6 months. Routine blood analysis, thyroid function, EEG, MRI, lipid profile did not reveal any abnormality. Ocular examination was also within normal limits. Olanzapine was suspected as a culprit for the above symptoms of patient, so it was replaced with quetiapine 25 mg/day. Patient showed partial recovery of symptoms within 1 week and complete recovery within 2 months of stopping olanzapine. Causality of olanzapine-induced blepharospasm as per WHO-UMC scale was probable. CONCLUSIONS: Olanzapine (atypical antipsychotics) should also be kept in the list of suspected drugs causing blepharospasm in psychotic patients on treatment although further similar evidences from observational studies and/or reports are needed to establish the causal relationship.
[Mh] Termos MeSH primário: Antipsicóticos/efeitos adversos
Benzodiazepinas/efeitos adversos
Blefarospasmo/induzido quimicamente
Blefarospasmo/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Esquema de Medicação
Feminino
Seres Humanos
Fatores de Tempo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 12794-10-4 (Benzodiazepines); N7U69T4SZR (olanzapine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170321
[Lr] Data última revisão:
170321
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160923
[St] Status:MEDLINE


  9 / 1181 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27078720
[Au] Autor:Raj A; Arya SK; Deswal J; Bamotra RK
[Ad] Endereço:a Department of Ophthalmology , Government Medical College and Hospital (GMCH) , Chandigarh , India.
[Ti] Título:Five-Year Retrospective Review of Cases with Benign Essential Blepharospasm and Hemifacial Spasm Presenting in a Tertiary Eye Care Center in North India.
[So] Source:Semin Ophthalmol;32(3):371-376, 2017.
[Is] ISSN:1744-5205
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Retrospective analysis of epidemiological and clinical characteristics of patients diagnosed with benign essential blepharospasm and hemifacial spasm who reported to the oculoplasty clinic of a tertiary eye care center in north India between January 2010 and April 2015 was carried out. Dry eye, as well as all the local factors that can cause blepharospasm or hemifacial spasm, was ruled out. Systemic evaluation was done to rule out any neurological disorder. A detailed history was taken to rule out any associated psychiatric disorders as well as use of any medication which could be responsible for dystonic movements. In every patient of hemifacial spasm, magnetic resonance imaging (MRI) of the brain was done for any facial nerve compression or tumor involving posterior fossa. Botulinum type A injections were given after assessing their requirements on the basis of guidelines given by Jankovic et al.
[Mh] Termos MeSH primário: Blefarospasmo/tratamento farmacológico
Toxinas Botulínicas Tipo A/uso terapêutico
Espasmo Hemifacial/tratamento farmacológico
Centros de Atenção Terciária
[Mh] Termos MeSH secundário: Adulto
Idoso
Blefarospasmo/complicações
Blefarospasmo/epidemiologia
Músculos Faciais
Feminino
Seguimentos
Espasmo Hemifacial/complicações
Espasmo Hemifacial/epidemiologia
Seres Humanos
Incidência
Índia/epidemiologia
Injeções Intramusculares
Masculino
Meia-Idade
Fármacos Neuromusculares/administração & dosagem
Estudos Retrospectivos
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neuromuscular Agents); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170612
[Lr] Data última revisão:
170612
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160415
[St] Status:MEDLINE
[do] DOI:10.3109/08820538.2015.1096401


  10 / 1181 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26020714
[Au] Autor:Kashkouli MB; Shahrzad S; Jazayeri AA; Abtahi MB
[Ad] Endereço:Eye Research Center, Ophthalmic Plastic and Reconstructive Unit, Rassoul Akram Hospital, Iran university of Medical Sciences, Tehran, Iran.
[Ti] Título:Treatment of Blepharospasm in Schwartz-Jampel Syndrome: Botulinum Toxin A Injection or Surgery.
[So] Source:Ophthal Plast Reconstr Surg;33(3S Suppl 1):S47-S49, 2017 May/Jun.
[Is] ISSN:1537-2677
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Schwartz-Jampel syndrome is an autosomal recessive disease that comprises facial and musculoskeletal deformity. Hereby, the authors report 2 cases of Schwartz-Jampel syndrome and surgical method of their management. The first case was a boy who was result of twin delivery whose sibling was completely normal. The second case was a girl who was the first child of her family. Both were born to a consanguineous marriage. Both had developed characteristic facial expressions of Schwartz-Jampel syndrome between 18 and 24 months of age. They had Botulinum toxin A injection (twice in the first and ones in the second case) with no improvement. Both were referred because of being functionally blind due to inability to open the eyelids around age 3.5 years. Orbicularis oculi myectomy, partial corrugator muscle excision, levator tucking, and lateral tarsal strip procedure was performed on both cases. No complication and no recurrence of eyelid contraction were observed after 4 years and 6 months follow up in the first and second case, respectively.
[Mh] Termos MeSH primário: Blefaroplastia/métodos
Blefarospasmo/tratamento farmacológico
Toxinas Botulínicas Tipo A/administração & dosagem
Pálpebras/cirurgia
Osteocondrodisplasias/complicações
[Mh] Termos MeSH secundário: Adulto
Blefarospasmo/etiologia
Músculos Faciais
Feminino
Seres Humanos
Lactente
Injeções Intramusculares
Masculino
Fármacos Neuromusculares/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; VIDEO-AUDIO MEDIA
[Nm] Nome de substância:
0 (Neuromuscular Agents); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150529
[St] Status:MEDLINE
[do] DOI:10.1097/IOP.0000000000000503



página 1 de 119 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde